A A A

Mary T. Szela, M.B.A., B.S.N.

Mary T. Szela, M.B.A., B.S.N.

Chief Executive Officer and President, Surefire Medical, Inc.
Mary T. Szela, M.B.A., has been a member of our board of directors since 2018.  Ms. Szela is currently the Chief Executive Officer and President of Surefire Medical Inc., which develops infusion technologies for cancer care. With nearly 30 years of experience in both the commercial and clinical arenas, Ms. Szela has built billion-dollar businesses, turned around faltering businesses, ignited growth in stagnant businesses, and devised innovative, differentiated product strategies. Prior to joining Surefire Medical as its CEO and President, Ms. Szela served as CEO of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics.  Prior to Novelion, she was CEO of Melinta Therapeutics.  Ms. Szela held ascending management positions at Abbott Laboratories, including President of the company's $8 billion U.S. pharmaceutical business.  Ms. Szela developed global brands such as Humira® and served as Vice President for global strategic marketing and services. In addition to serving on Alimera's board, Ms. Szela currently serves as a member of the board of directors for Surefire Medical, Inc., Coherus Biosciences and Macrolide Pharmaceuticals.  Ms. Szela earned an M.B.A. and a B.S. in nursing, both from the University of Illinois.
Independent Director